EOLS Q1 2022 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$34M+177.0% YoY

Gross Profit

$21M61.0% margin

Operating Income

-$15M-45.6% margin

Net Income

-$18M-51.6% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-2.2%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$153M

Stockholders' Equity

$67M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$12M	+177.0%
Gross Profit	$21M	$7M	+182.3%
Operating Income	-$15M	$8M	-292.5%
Net Income	-$18M	$6M	-373.4%

Revenue Segments

Product

$33M100%

Geographic Segments

CANADA

$682,000100%